EA6192 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

Study Number: EA6192 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

Please Note:

This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.

Available Sites

• Missouri Baptist Medical Center

Contact Person(s)

• David Winkfield 314-996-4617

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.